Pharmaceutical industry
The US Food and Drug Administration (FDA) has raised concerns over AstraZeneca's diabetes drug Onglyza ahead of a committee meeting to discuss the safety of a class of drugs called DPP-4 inhibitors. An FDA briefing document pointed to increases in all-cause mortality among patients taking Onglyza, particularly due
Pharmaceutical industry
WuXi PharmaTech's (NYSE: WX) partnership with MedImmune has reached a significant milestone as the Investigational New Drug (IND) application for WuXi MedImmune's novel anti-IL6 monoclonal antibody has been accepted for review by the China Food and Drug Administration (CFDA). This novel biologic is intended for the
Pharmaceutical industry
Illumina Inc., a major developer of life science tools for large-scale genetic analysis, has recently formed an alliance with Merck Serono, the biopharmaceuticals business of Germany's Merck KGaA. The partnership aims to consolidate Illumina's foothold in the multi-billion gene sequencing market through strategic collaborations with therapeutics
Pharmaceutical industry
Illumina, a leading next-generation sequencing (NGS) technology company, has formed a partnership with Merck Serono to develop a universal oncology diagnostic test. This collaboration aims to create a comprehensive tool for precision medicine in cancer treatment, allowing for the detection and measurement of multiple genetic variants simultaneously. The partnership will
Pharmaceutical industry
AstraZeneca plc, a global biopharmaceutical company, has been the subject of several analyst ratings in recent days. Deutsche Bank reaffirmed its hold rating on the company's shares, maintaining a target price of GBX 4,800 ($72.40). This move is part of a broader trend of analyst reassessments,
Pharmaceutical industry
European ADRs experienced a significant decline, with the Bank of New York Mellon Europe ADR Index contracting by 0.63% to 140.90. The downturn was widespread, with various sectors contributing to the losses. National Bank of Greece led the decline in continental Europe, falling by 12.1%, while miners
Pharmaceutical industry
Shares of Oxford Instruments plc (OXIG) continue to draw attention from analysts, with Berenberg Bank reiterating its buy rating and price target of GBX 1,360 ($20.53) on the stock. This guidance follows a series of updates from various analysts, including Investec, Liberum Capital, Numis Securities Ltd, and Beaufort
Pharmaceutical industry
As of Monday, Jan. 12, 2015, the Health Care sector was trading up 0.3% versus the S&P 500, which was down 0.8%. The sector's mixed performance was underscored by the strong performance of Foundation Medicine, Hologic, Allergan, Biogen Idec, and Actavis, which were up
Pharmaceutical industry
Packard's BioScience Company and AstraZeneca have extended their partnership, with Packard's technology set to aid AstraZeneca in rapidly identifying promising compounds for drug discovery. The expanded contract, worth $5.5 million, will see Packard's BRET2(TM) technology used to screen AstraZeneca's combinatorial
Pharmaceutical industry
Financial markets are bracing for a pivotal week with several influential companies set to announce quarterly results, including WPP, AstraZeneca, and Pilkington, which could have a significant impact on the overall stock market performance. Revelations from these announcements may intensify concerns over the pace of global economic growth, particularly in
Pharmaceutical industry
Preliminary results from phase I clinical trials suggest that the novel anticancer compound, IRESSA (ZD1839), shows promise in treating non-small cell lung cancer. Researchers from AstraZeneca presented the findings at the American Society of Clinical Oncology (ASCO) annual meeting in New Orleans. The study involved 64 patients who had received
Pharmaceutical industry
A new comparative study between Prilosec (omeprazole) and Nexium (esomeprazole magnesium) has shown that the latter provides higher healing rates in the treatment of erosive esophagitis (EE). Additionally, patients receiving Nexium experienced a higher proportion of sustained heartburn resolution. This study is consistent with previous results presented at Digestive Disease
